RiboBio Unveils First Preclinical Data for Three Investigational Oligonucleotide Therapeutics Targeting Cardiovascular and Metabolic Diseases

On September 4, Ribo Life Science announced that the company had showcased for the first time at the ESC Congress 2023, held in Amsterdam from August 25-28, 2023.Cardiovascular and Metabolic Diseases FieldResearch data on the three pipeline products, respectively targetingThrombosis、DyslipidemiaAndHypertensionThe research results show that the use of RIBO-GalSTAR, a liver-targeting platform technology independently developed by Ribo Life Science, can highly specifically, potently, and persistently inhibit pathogenic genes, achieving the treatment of related diseases.

RBD4059YesGalNAc-siRNA Drug Targeting Coagulation Factor XI (FXI)FXI is a key molecule in the intrinsic coagulation pathway. An increasing number of studies have shown that inhibiting FXI can block the intrinsic coagulation pathway, offering a new and effective antithrombotic strategy with a low risk of bleeding for clinical patients. Preclinical research data shows,RBD4059 Exhibits Potent and Sustained Inhibition of FXI Expression and Activity, which is expected to have long-lasting efficacy in clinical settings and improve patient compliance. RBD4059 is currently in Phase 1 clinical trials.

RBD5044Is a targetedApolipoprotein CIII (ApoC3)GalNAc-siRNA DrugsHypertriglyceridemia (HTG) is one of the most important lipid disorder diseases, which can cause endothelial dysfunction, accelerate the occurrence and development of atherosclerosis, and increase the risk of acute pancreatitis.Targeting ApoC3 through the RNAi mechanism is considered to effectively and sustainably reduce plasma triglycerides and ApoB-containing lipoproteins in patients, thereby saving the lives of those with atherosclerotic cardiovascular disease.Non-clinical safety and efficacy study data show that RBD5044 has good efficacy and a long-lasting effect. This candidate drug is currently in Phase 1 clinical trials.

R0797070It is a GalNAc-siRNA molecule targeting hepatic angiotensinogen (AGT).Preclinical study data show that the candidate drug can efficiently inhibit liver AGT expression, continuously reduce blood pressure, and significantly improve left ventricular hypertrophy. R0797070 is expected to provide...Patients with refractory hypertensionProvide better blood pressure control therapy and bring additional benefits to patients in terms of cardiac protection. According to the news release from Ribo Life Science, the product is about to initiate IND-enabling studies, and new indications beyond hypertension will be explored in future clinical trials.

Global R&D President of Ribo Life ScienceDr. Gan LimingSaid: "At the ESC conference, we have seen that RNAi therapies are increasingly being used to treat cardiovascular and metabolic diseases, especially for chronic disease treatment as well as primary and secondary prevention. By specifically targeting pathogenic genes in the liver, we can treat a wide range of cardiovascular diseases, including hyperlipidemia, hypertension, thrombotic disorders, and heart failure. With Ribo Life Science's extensive product pipeline in the cardiovascular field and our continuously growing innovative capabilities, we are highly confident in accelerating the advancement of our research and development to benefit patients worldwide with unmet medical needs."